Ranked #4,679 of 8,699 institutional investors
Acorn Capital Advisors, LLC
New York, NY
$332M
US stock portfolio at live prices · today −$649K (−0.20%)
Live prices, last trade 11:18 AM ET
- Value at quarter end (Q3 2026)
- $364M
- Change from Q2 2026
- −$2.5M (−0.68%)
- Positions
- 17 · 2 new, 0 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$87.6M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesCGON 28.0%PBYI 8.87%TRVI 8.71%CADL 5.49%JBIO 4.59%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| CGON CG Oncology, Inc. | 1,131,500 | $92.9M | 28.0% | Unchanged |
| PBYI Puma Biotechnology, Inc. | 4,131,299 | $29.4M | 8.87% | Unchanged |
| TRVI Trevi Therapeutics, Inc. | 2,144,844 | $28.9M | 8.71% | Unchanged |
| CADL Candel Therapeutics, Inc. | 3,497,948 | $18.2M | 5.49% | Unchanged |
| JBIO Jade Biosciences, Inc. | 986,760 | $15.2M | 4.59% | Unchanged |
| VSTM Verastem, Inc. | 1,469,153 | $9.8M | 2.95% | Unchanged |
| OKUR OnKure Therapeutics, Inc. | 2,839,674 | $7.9M | 2.37% | Unchanged |
| AURA Aura Biosciences, Inc. | 1,025,349 | $7.1M | 2.13% | Added +10% |
| ENGN enGene Therapeutics Inc. | 3,811,782 | $6.8M | 2.04% | Added +200% |
| ANTX AN2 Therapeutics, Inc. | 1,300,000 | $6.8M | 2.04% | New |
| BCAX Bicara Therapeutics Inc. | 668,381 | $6.0M | 1.82% | Added +4% |
| TARA Protara Therapeutics, Inc. | 1,752,115 | $4.0M | 1.20% | Unchanged |
| ANNX Annexon, Inc. | 1,136,974 | $3.7M | 1.12% | New |
| WHWK Whitehawk Therapeutics, Inc. | 932,139 | $2.9M | 0.87% | Reduced −18% |
| LONA LeonaBio, Inc. | 1,144,416 | $2.7M | 0.80% | Added +80% |
| QTTB Q32 Bio Inc. | 216,171 | $1.9M | 0.56% | Unchanged |
| KPTIQ Karyopharm Therapeutics Inc. | 1,222,019 | $42K | <0.1% | Reduced −20% |